Perinase

50 mcg/spray : This strength is indicated for prophylaxis and treatment of seasonal & perennial allergic rhinitis. Prevention of recurrence of nasal polyps following surgical removal. 93 mcg/spray : This strength is indicated for chronic rhinosinusitis with or without nasal polyps in adults.

Following topical administration into the nasal mucosa, Fluticasone propionate produces anti-inflammatory and vasoconstrictor effects. The exact mechanism of these actions remains unknown but may involve a reduction in the following: number of mediator cells (basophil, leukocytes and mast cells) at the epithelial level, number of eosinophils, the sensitivity of sensory nerves to mechanical stimuli, secretory response to cholinergic receptor stimulation, and fibroblast activity. Other mechanisms may involve - inhibition of capillary dilation and permeability, stabilization of lysosomal membranes and subsequent prevention of release of proteolytic enzymes.

Fluticasone Propionate (50 mcg/spray):

Adults : 2 sprays in each nostril once daily, preferably in the morning. In some cases, 2 sprays in each nostril twice daily may be required. Total daily doses of 200 mcg (4 sprays) should not generally be exceeded.

Children (4 to 11 years of age) : 1 spray in each nostril once daily. In some cases, 1 spray in each nostril twice daily may be required. Total daily doses of 100 mcg 2 sprays should not generally be exceeded.

Children below 4 years : The safety and effectiveness of Fluticasone Propionate nasal spray in children below 4 years of age have not been established.

Fluticasone Propionate (93 mcg/spray) : 1 spray or 2 sprays per nostril twice daily. The maximum total daily dosage should not exceed 2 sprays in each nostril twice daily (total daily dose of 744 mcg).

Patients should use Fluticasone Propionate Nasal Spray at regular intervals as directed since its effectiveness depends on its regular use. Or as directed by the physician.

Fluticasone Propionate nasal spray is contraindicated in patients with a hypersensitivity to any of its ingredients.

Perinase nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. With the nasal spray, drying of the nose and throat, unpleasant taste and smell and an increase in the incidence of nosebleeds may occur.

There are no adequate and well-controlled studies in pregnant women. Fluticasone Propionate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Fluticasone Propionate is excreted in human breast milk. Because other corticosteroids are excreted in human milk, caution should be exercised when Fluticasone Propionate nasal spray is administered to a nursing woman.

Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma and increased intraocular pressure have been reported following the intranasal application of corticosteroids, including Perinase. Although systemic effects have been minimal with recommended doses of Perinase nasal spray. Potential risk increases with larger doses. Therefore, larger than recommended doses of Perinase nasal spray should be avoided.

Keep all medicines out of reach of the children. Store in a cool and dry place protected from light.